C-Rad AB (publ) (CRAD-B.ST)
SEK 29.9
(-0.17%)
SEK 29.9
(-0.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 122.4 Million SEK | 26.67% |
| 2022 | 96.63 Million SEK | 27.79% |
| 2021 | 75.61 Million SEK | 6.9% |
| 2020 | 70.73 Million SEK | -5.0% |
| 2019 | 74.45 Million SEK | 40.56% |
| 2018 | 52.97 Million SEK | 13.55% |
| 2017 | 46.64 Million SEK | 48.09% |
| 2016 | 31.5 Million SEK | -6.19% |
| 2015 | 33.57 Million SEK | 2.92% |
| 2014 | 32.62 Million SEK | 37.41% |
| 2013 | 23.74 Million SEK | 8.61% |
| 2012 | 21.86 Million SEK | 20.19% |
| 2011 | 18.18 Million SEK | -7.69% |
| 2010 | 19.7 Million SEK | 31.18% |
| 2009 | 15.02 Million SEK | 12.65% |
| 2008 | 13.33 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 139.9 Million SEK | -13.64% |
| 2024 Q2 | 162 Million SEK | 16.97% |
| 2024 Q1 | 138.5 Million SEK | 13.15% |
| 2023 Q4 | 122.4 Million SEK | 1.83% |
| 2023 Q3 | 120.2 Million SEK | 27.06% |
| 2023 Q2 | 94.6 Million SEK | 3.73% |
| 2023 Q1 | 91.2 Million SEK | -5.62% |
| 2023 FY | 122.4 Million SEK | 26.67% |
| 2022 Q3 | 72.6 Million SEK | -5.96% |
| 2022 Q1 | 70.9 Million SEK | -6.24% |
| 2022 FY | 96.63 Million SEK | 27.79% |
| 2022 Q2 | 77.2 Million SEK | 8.89% |
| 2022 Q4 | 96.63 Million SEK | 33.1% |
| 2021 Q4 | 75.61 Million SEK | 14.92% |
| 2021 FY | 75.61 Million SEK | 6.9% |
| 2021 Q2 | 64.7 Million SEK | 1.57% |
| 2021 Q3 | 65.8 Million SEK | 1.7% |
| 2021 Q1 | 63.7 Million SEK | -9.94% |
| 2020 FY | 70.73 Million SEK | -5.0% |
| 2020 Q1 | 55.6 Million SEK | -25.33% |
| 2020 Q2 | 43.5 Million SEK | -21.76% |
| 2020 Q3 | 62.6 Million SEK | 43.91% |
| 2020 Q4 | 70.73 Million SEK | 12.99% |
| 2019 Q4 | 74.45 Million SEK | -7.04% |
| 2019 Q2 | 81.5 Million SEK | 29.37% |
| 2019 Q1 | 63 Million SEK | 18.93% |
| 2019 FY | 74.45 Million SEK | 40.56% |
| 2019 Q3 | 80.1 Million SEK | -1.72% |
| 2018 Q3 | 48.1 Million SEK | -13.49% |
| 2018 Q2 | 55.6 Million SEK | 23.56% |
| 2018 Q1 | 45 Million SEK | -3.53% |
| 2018 FY | 52.97 Million SEK | 13.55% |
| 2018 Q4 | 52.97 Million SEK | 10.13% |
| 2017 Q1 | 35 Million SEK | 11.11% |
| 2017 Q4 | 46.64 Million SEK | -9.77% |
| 2017 FY | 46.64 Million SEK | 48.09% |
| 2017 Q3 | 51.7 Million SEK | 12.46% |
| 2017 Q2 | 45.97 Million SEK | 31.34% |
| 2016 FY | 31.5 Million SEK | -6.19% |
| 2016 Q4 | 31.5 Million SEK | -16.97% |
| 2016 Q2 | 25.17 Million SEK | -49.53% |
| 2016 Q1 | 49.87 Million SEK | 48.53% |
| 2016 Q3 | 37.93 Million SEK | 50.73% |
| 2015 Q1 | 32.14 Million SEK | -1.46% |
| 2015 FY | 33.57 Million SEK | 2.92% |
| 2015 Q4 | 33.57 Million SEK | 47.08% |
| 2015 Q3 | 22.82 Million SEK | -9.07% |
| 2015 Q2 | 25.1 Million SEK | -21.9% |
| 2014 Q3 | 19.65 Million SEK | 4.63% |
| 2014 Q4 | 32.62 Million SEK | 66.03% |
| 2014 Q1 | 19.65 Million SEK | -17.22% |
| 2014 FY | 32.62 Million SEK | 37.41% |
| 2014 Q2 | 18.78 Million SEK | -4.45% |
| 2013 Q1 | 29.53 Million SEK | 35.08% |
| 2013 Q4 | 23.74 Million SEK | 18.95% |
| 2013 FY | 23.74 Million SEK | 8.61% |
| 2013 Q2 | 20.57 Million SEK | -30.34% |
| 2013 Q3 | 19.96 Million SEK | -2.96% |
| 2012 Q4 | 21.86 Million SEK | 19.83% |
| 2012 Q3 | 18.24 Million SEK | 3.16% |
| 2012 FY | 21.86 Million SEK | 20.19% |
| 2012 Q1 | 18.34 Million SEK | 0.88% |
| 2012 Q2 | 17.68 Million SEK | -3.61% |
| 2011 Q4 | 18.18 Million SEK | -4.54% |
| 2011 FY | 18.18 Million SEK | -7.69% |
| 2011 Q1 | 17.1 Million SEK | -13.21% |
| 2011 Q2 | 16.49 Million SEK | -3.53% |
| 2011 Q3 | 19.05 Million SEK | 15.5% |
| 2010 FY | 19.7 Million SEK | 31.18% |
| 2010 Q3 | 14.33 Million SEK | -5.55% |
| 2010 Q1 | 15.13 Million SEK | 0.76% |
| 2010 Q2 | 15.18 Million SEK | 0.3% |
| 2010 Q4 | 19.7 Million SEK | 37.42% |
| 2009 Q4 | 15.02 Million SEK | 59.37% |
| 2009 Q2 | 9.28 Million SEK | -9.73% |
| 2009 Q1 | 10.28 Million SEK | -22.85% |
| 2009 FY | 15.02 Million SEK | 12.65% |
| 2009 Q3 | 9.42 Million SEK | 1.5% |
| 2008 FY | 13.33 Million SEK | 0.0% |
| 2008 Q4 | 13.33 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -1012.93% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 95.423% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 95.423% |
| Arcoma AB | 33.3 Million SEK | -267.512% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 62.875% |
| BICO Group AB (publ) | 3.26 Billion SEK | 96.251% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 56.27% |
| CellaVision AB (publ) | 212.32 Million SEK | 42.352% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -762.154% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -1681.935% |
| Duearity AB (publ) | 17.53 Million SEK | -598.232% |
| Dignitana AB (publ) | 37.56 Million SEK | -225.818% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -518.182% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.504% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -494.166% |
| Iconovo AB (publ) | 14.55 Million SEK | -741.012% |
| Integrum AB (publ) | 22.07 Million SEK | -454.527% |
| Luxbright AB (publ) | 7 Million SEK | -1648.541% |
| Mentice AB (publ) | 163.55 Million SEK | 25.162% |
| OssDsign AB (publ) | 105.25 Million SEK | -16.287% |
| Paxman AB (publ) | 44.5 Million SEK | -175.001% |
| Promimic AB (publ) | 16.15 Million SEK | -657.613% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -96.883% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -475.242% |
| ScandiDos AB (publ) | 37.18 Million SEK | -229.156% |
| Sectra AB (publ) | 1.64 Billion SEK | 92.543% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -177.79% |
| Senzime AB (publ) | 58.06 Million SEK | -110.798% |
| SpectraCure AB (publ) | 14.97 Million SEK | -717.362% |
| Stille AB | 172.64 Million SEK | 29.101% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 96.663% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 51.151% |